Dose Escalation of Luspatercept on Trial and Real-World Data
Guillermo Garcia-Manero, MD, addresses clinical research investigating luspatercept dose titration practices in patients with lower-risk MDS.
Video content above is prompted by the following:
- Per the COMMANDS trial schema, luspatercept was initiated at 1.0 mg/kg with titration allowed at 2 levels to a maximum of 1.75 mg/kg.
- Please discuss the efficacy data associated with up titration and the number of participants who required dose escalation in the trial.
- At the 2024 EHA Congress, data was presented on real-world dose escalation of luspatercept and clinical outcomes. Please discuss the findings and the impact on TI for patients originally TD and for patients for patients NTD prior to dose escalation.
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More
Lower Cardiac Risks Found With Second-Generation BTK Inhibitors in B-Cell Hematologic Disorders
December 12th 2024In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.
Read More
